What Candel Therapeutics Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 3 | 5 |
| Total trades | 4 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 125,000 | 675,458 |
| Disposed | 287,245 | 317,692 |
| Net activity | −162,245 | +357,766 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Tak Paul Peter | Chief Executive Officer | Sep 11 | Open-market sale · S | −59,379 | $10.46 | −$621K | 113,321 |
| Tak Paul Peter | Chief Executive Officer | Sep 10 | Open-market sale · S | −220,866 | $11.50 | −$2.54M | 172,700 |
| Tak Paul Peter | Chief Executive Officer | Sep 10 | Exercise / conversion · M | +125,000 | $1.55 | +$194K | 393,566 |
| Tyagarajan Seshu | Chief Technology Officer | Aug 17 | Open-market sale · S | −7,000 | $12.00 | −$84K | 76,865 |
| Barone Francesca | Chief Scientific Officer | Jun 29 | Open-market sale · S | −23,447 | $10.06 | −$236K | 77,362 |
| Tyagarajan Seshu | Chief Technology Officer | Jun 29 | Open-market sale · S | −7,000 | $10.02 | −$70.2K | 83,865 |
| Manning Paul B | Director | Feb 23 | Open-market buy · P | +550,458 | $5.45 | +$3M | 2,763,527 |
| Nichols Garrett | Chief Medical Officer | Jul 28 | Open-market sale · S | −937 | $6.98 | −$6.54K | 52,493 |
| Nichols Garrett | Chief Medical Officer | Jul 28 | Exercise / conversion · M | +937 | $1.29 | +$1.21K | 53,430 |
| Nichols Garrett | Chief Medical Officer | Jun 30 | Open-market sale · S | −781 | $5.04 | −$3.94K | 52,493 |
| Nichols Garrett | Chief Medical Officer | Jun 30 | Exercise / conversion · M | +781 | $1.29 | +$1.01K | 53,274 |
| Barone Francesca | Chief Scientific Officer | Jun 25 | Grant / award · A | +4,282 | $4.67 | +$20K | 100,809 |
| Nabel Gary J. | Director | Jun 25 | Grant / award · A | +5,353 | $4.67 | +$25K | 5,353 |
| Loggia Nicoletta | Director | Jun 25 | Grant / award · A | +2,141 | $4.67 | +$10K | 2,141 |
| Martell Christopher | Director | Jun 25 | Grant / award · A | +111,349 | $4.67 | +$520K | 111,349 |
| Tyagarajan Seshu | Chief Technology Officer | Jun 25 | Grant / award · A | +5,353 | $4.67 | +$25K | 90,865 |
| Papa Joseph C | Director | Jun 25 | Grant / award · A | +64,239 | $4.67 | +$300K | 64,239 |
| Manning Paul B | Director | Jun 25 | Grant / award · A | +1,070,663 | $4.67 | +$5M | 2,213,069 |
| Tak Paul Peter | Chief Executive Officer | Jun 25 | Grant / award · A | +42,826 | $4.67 | +$200K | 268,566 |
| Schoch Charles | Chief Financial Officer | Jun 25 | Grant / award · A | +5,353 | $4.67 | +$25K | 43,391 |
Loading...
